Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Stroke. 2017 Mar 30;48(5):1369–1375. doi: 10.1161/STROKEAHA.117.016850

Figure 5.

Figure 5

(A) CD163 immunoreactivity and protein levels in primary cultured neurons treated with hemoglobin (0 or 20μM) with or without deferoxamine (5μM) pretreatment. Scale bar= 50μm. (B) Media LDH levels 24 hours after the treatment of hemoglobin (0 or 20μM) with or without deferoxamine (5μM). Values are mean ± SD, *p<0.05, # p<0.01 vs. the other groups.